CHELATION STOPS HEART ATTACKS PART 1
NOW PROVEN IN MAINSTREAM MEDICINE
TWO NEW SCIENTIFIC TRIALS
Chelation is a method of removing heavy metals from the body. I have been performing chelation on myself for over 15 years. I have developed several protocols for evaluating your heavy metals, which is a process called chelation. Depending the review of the patient’s heavy metal report then heavy metal detox/chelation is preformed.
Recently, the National Institutes of Health funded a 7 year study called TACT (trial to assess Chelation therapy). It was a double blind controlled study performed not only by prominent chelation doctors, but also by university cardiologists.
One of the lead doctors is Gervasio A. Lamas, M.D., is chief of Cardiology at the Mt. Sinai Medical Center in Miami Beach, Florida. I encourage the readers to read his studies on line.
THE TRIAL FOUND THAT THOSE RECEIVING THE REAL IV CHELATION HAD FEWER HEART ATTACKS AND DEATH RATES THAN THOSE GETTING PLACEBOS.
THIS WAS REPORTED IN THE TACT TRIAL IN JAMA MARCH 2013.
Furthermore, Chelation reduced deaths from heart attack by 18% and by over 39% for diabetics. This was presented at the November 2012, meeting by the American Heart Association, and the results by main stream doctors were mixed. The real problem with the study was that the placebo that was used was olive oil and therefore is not a placebo because olive oil is quite healthy for the heart and vasculature.
ACCORDING TO DR. LAMAS, THE CARDIOLOGIST MENTIONED ABOVE, THE TRIAL HE ASSESSED WAS THE EFFECTS OF EDTA BASED INFUSIONS IN 1,078 PATIENTS ABOVE AGE 50 WITH PRIOR HISTORY OF MYOCARDIAL INFARCTION AND A SERUM CREATININE OF 2.0 OR LESS.
DR. LAMAS SAID WE FOUND A MODEST REDUCTION IN THE PRIMARY END POINT, COMBINATION OF MORTALITY, RECURRENT MI, STROKE, CORONARY REVASCULARIZATION, OR HOSPITALIZATION FOR ANGINA IN PATIENTS THAT RECEIVED THE INFUSION WHEN COMPARED TO THOSE WHO DID NOT.
In a pre specified subgroup analysis, he reported a significant interaction between the diagnosis of diabetes and the EDTA infusion.
Dr. Lamas goes on to say that an in depth analysis of the effect of EDTA in 633 diabetic patients was done later.
Dr. Llamas found a 41% relative risk reduction primary cardiovascular end-point, a combination of cardiovascular mortality, non fatal stroke or non fatal MI in diabetics who receive EDTA infusions as compared to patients that receive placebo (p=0.0002). There was, furthermore, a 43% reduction and all caused mortality by infusions in diabetic patients (p=0.011). The 5-year number needed to prevent 1 event was 7. There is nothing else like this in diabetes according to Dr. Lamas.
Dr. Lamas goes on to say that EDTA chelations were used for many years by practitioners throughout the world. He says the extreme benefit in diabetic patients was unexpected to those of us who do not practice chelation therapy. Because of the unexpected nature of findings, conventional cardiologist, colleagues and leaders in the field, initially had an irrational reaction and rejected our findings. As the robust nature of these findings become more evident, TACT has been viewed as an outliner of sorts, one that requires confirmation, he goes on to say we should advocate that a true scientist will look at the trial objectively.
Dr. Lamas goes on to say that EDTA is safe, and reduces events in diabetic patients with a prior heart attack by 41%. Dr. Lamas says that he advocates individual clinician patient teams to evaluate whether chelation with EDTA should be part of the treatment program in these patients.
THE SECOND NEW STUDY
And as reported in the AMERICAN HEART JOURNAL IN JULY 2014
Another study to assess high dose vitamins with minerals with chelation was performed. This was a double blind, placebo controlled, 2 x factorial multicenter randomized trial of 1,708 post myocardial infarction patients greater than 50 years of age with a creatinine less than 2. They were randomized to receive either 40 EDTA agulation or placebo infusions, plus 6 caplets daily of 28 component multi-vitamin, multi-mineral mixture of placebo. The primary end-point was a composite of total mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for angina. The median age was 65 years, 18% were female, 37% were diabetic, 83% had prior coronary revascularization, and 73% were on statins.
The five-year Kaplan-Meier estimate for the primary end-point was 31.9% in the chelation plus vitamin group, and 40.2% in the placebo group. THE REDUCTION IN PRIMARY END POINT BY DOUBLE ACTIVE TREATMENT COMPARED WITH DOUBLE PLACEBO.
We currently have two peer reviewed double blind studies on chelation, one with the initial TACT study, which was a multi-center trial. The results as described above were significant especially in the diabetic group. Furthermore, chelation reduced deaths from heart attacks by 18% and by over 39% for diabetics.
We now have the American Heart Journal with its article showing that in stable post-MI patients on evidence based medical therapy, the combination of oral high dose vitamins and chelation therapy, compared with double placebo REDUCE CLINICALLY IMPORTANT CARDIOVASCULAR EVENTS TO THE EXTENT THAT WAS SIGNIFICANT.
That was written in the American Heart Journal and can be viewed on pubmed.com. In addition, the older TACT study can also be viewed on pubmed.com
Both these studies are peer reviewed double blind and show positive effects, as described above, with chelation. When you review the study in depth, the TACT study used olive oil as a placebo. Olive oil is known cardio protective, so, hopefully in the next chelation study there will not be olive oil, which is a cause of heart health anyway, and should never have been used as a placebo.
In reviewing both these studies, I am reminded of the early days of controversy over whether increasing the omega-3 oils could reduce the risks of heart attack and stroke. Several early reports claim that omega-3 oils reduced risk of cardiovascular and peripheral disease, but they were earlier ignored by prestigious main stream medical journals. But soon, main stream medicine caught on.
When I exam the TACT study in great detail, I noticed the placebo they used was olive oil. I quickly realized that the so called “placebo” was in fact an active inhibitor of atherosclerosis, much like fish oil. When an actual placebo was used, fish oil won hands down.
I have been doing chelation on myself for about 15 years. In 2000, I was extremely ill with a PET scan compatible with lymphoma and heart disease with angina. I am now symptom free and disease free. Having interviewed many practitioners and many patients over the last 15 years, I myself, feel that chelation does treat vascular disease, as noted in a peer reviewed double blind literature. I feel that more chelation studies with EDTA are needed, but sufficient to say with the two studies I have, I feel that it is a viable option for some patients who are interested.
Other sections of this site describe how heavy metals can be toxins, but in this section I have addressed CHELATION with EDTA infusions, along with vitamins. I have now presented you two peer review, double blind studies showing a positive effect, especially in the diabetic patient.
The author’s information is multi-center and these include:
• Mt. Sinai Medical Center, Miami Beach Florida
• National Heart, Lung and Blood Institute, Bethesda, Maryland
• Duke Clinical Institute, Durham, North Carolina
• National Center for Complementary Alternative Medicine, Bethesda, Maryland
• Brigham and Woman’s Hospital at Harvard Medical School, Boston, Massachusetts
• University of Kansas Medical Center, Kansas City, Kansas
If you are interested in learning more about chelation, heavy metal detox, and an integrative approach to coronary disease, congestive heart failure and arrhythmia, you might benefit from an integrative consult.
Other therapies used are IV Myers cocktail, IV vitamin C, IV Ozone, IV Plaquex, and others including PEMF MAGNET THERAPY, HBO, PHOTON THERAPY AND MICROCURRENT.
Dr. Silver also addresses mitochondrial function, cardiac metabolism, infections, neurologic diseases and complex chronic diseases, such as cancer. Please see other areas of this site.
If you feel you might benefit from this integrative approach, please call my office for an appointment.
Best in health,
Dean R. Silver